Literature DB >> 8864798

Pharmacokinetics of nitazoxanide after single oral dose administration in 6 healthy volunteers.

A Stockis1, X Deroubaix, R Lins, B Jeanbaptiste, P Calderon, J F Rossignol.   

Abstract

The objective of this study was to gather first information on the time course of plasma concentrations and urinary excretion of the antiprotozoal nitazoxanide (N) and to identify potential metabolites in healthy subjects after a single oral dose of 500 mg of nitazoxanide. The clinical trial was conducted as an open single oral dose study in 6 healthy male subjects. After a standardized continental breakfast the subjects took a single oral dose of 500 mg nitazoxanide (coated tablet) with 100 ml tap water. The plasma concentration and the urinary excretion of nitazoxanide (N), desacetyl-nitazoxanide (DN), aminonitrothiazole (ANT), acetylsalicylate (AS), salicylate (S), gentisate (G) and salicylurate (SU) were monitored up to 72 h after administration. The only measurable species in plasma was DN, which reached a Cmax of 1.9 mg/l (range 1.1-2.5) 2-6 h after dosing, and an AUC of 3.9-11.3 mg x h/l. Its terminal half-life ranged from 1.03 to 1.6 h. DN was extensively bound to plasma proteins (> 97.5%). Only 8% of the dose was recovered in the urine, in the form of DN (5%), SU (3%), and traces of ANT (0.1%). In vitro N was very rapidly hydrolyzed to DN by plasma esterases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8864798

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther        ISSN: 0946-1965            Impact factor:   1.366


  25 in total

Review 1.  Amino Acids in the Development of Prodrugs.

Authors:  Nuno Vale; Abigail Ferreira; Joana Matos; Paula Fresco; Maria João Gouveia
Journal:  Molecules       Date:  2018-09-11       Impact factor: 4.411

2.  Nitazoxanide : A Broad Spectrum Antimicrobial.

Authors:  Nishith Singh; S Narayan
Journal:  Med J Armed Forces India       Date:  2011-07-21

3.  Inhibitory activities of epidermal growth factor receptor tyrosine kinase-targeted dihydroxyisoflavone and trihydroxydeoxybenzoin derivatives on Sarcocystis neurona, Neospora caninum, and Cryptosporidium parvum development.

Authors:  G Gargala; A Baishanbo; L Favennec; A François; J J Ballet; J-F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  2005-11       Impact factor: 5.191

4.  In vitro evaluation of activities of nitazoxanide and tizoxanide against anaerobes and aerobic organisms.

Authors:  L Dubreuil; I Houcke; Y Mouton; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1996-10       Impact factor: 5.191

5.  Activity of nitazoxanide and tizoxanide against Mycobacterium tuberculosis in vitro and in whole blood culture.

Authors:  Elizabeth P Harausz; Keith A Chervenak; Caryn E Good; Michael R Jacobs; Robert S Wallis; Manuel Sanchez-Felix; W Henry Boom
Journal:  Tuberculosis (Edinb)       Date:  2016-03-22       Impact factor: 3.131

6.  Nitazoxanide, a potential drug for eradication of Helicobacter pylori with no cross-resistance to metronidazole.

Authors:  F Mégraud; A Occhialini; J F Rossignol
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

7.  In Vitro Susceptibility of Canine Influenza A (H3N8) Virus to Nitazoxanide and Tizoxanide.

Authors:  Laura V Ashton; Robert L Callan; Sangeeta Rao; Gabriele A Landolt
Journal:  Vet Med Int       Date:  2010-08-12

8.  Interferon Stimulated Gene Expression in HIV/HCV Coinfected Patients Treated with Nitazoxanide/Peginterferon-Alfa-2a and Ribavirin.

Authors:  Tess Petersen; Yu-Jin Lee; Anu Osinusi; Valerianna K Amorosa; Crystal Wang; Minhee Kang; Roy Matining; Xiao Zhang; Diana Dou; Triin Umbleja; Shyam Kottilil; Marion G Peters
Journal:  AIDS Res Hum Retroviruses       Date:  2016-03-14       Impact factor: 2.205

9.  Nitazoxanide in treatment of Helicobacter pylori: a clinical and in vitro study.

Authors:  Yvonne Guttner; Helen M Windsor; Charlie H Viiala; Leon Dusci; Barry J Marshall
Journal:  Antimicrob Agents Chemother       Date:  2003-12       Impact factor: 5.191

Review 10.  Nitazoxanide: a review of its use in the treatment of gastrointestinal infections.

Authors:  Vanessa R Anderson; Monique P Curran
Journal:  Drugs       Date:  2007       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.